Strategic partner
Oxeltis S.A. (Oxeltis) and Molecular Forecaster Inc. (MFI) are excited to announce a strategic partnership leveraging the strengths of both organizations to offer seamless integration of in silico design with high-quality chemical synthesis.
Under the collaboration, Oxeltis and MFI will help organizations prioritize candidates, reduce design cycles, and boost productivity by integrating MFI’s predictive modeling and customized, collaborative CADD solutions with Oxeltis’ wet lab-based medicinal chemistry design and synthesis. The strategic partnership further benefits clients by streamlining project management and administration between the organizations, without sacrificing the individual expertise of either.
“This collaboration is an opportunity to outsource critical research activities to companies with highly specialized and complementary research expertise, and a proven and productive working relationship,” says Jean-Marc Allaire, CEO of Oxeltis. “Whether organizations need virtual screening campaigns, synthesis of focused libraries, or fully integrated support for early discovery programs, our combined knowledge and approaches enable us to customize innovative and efficient solutions for clients that set them up for the greatest success.”
Jean-Marc ALLAIRE, M.D., CEO & Co-founder of Oxeltis
“At MFI, we believe the primary benefit of computational drug design is to help humans learn faster so they can make smarter, more strategic decisions that save time, money, and lives,” says Josh Pottel, MFI’s CEO. “We also believe collaboration is key to achieving the greatest possible results. Forming complementary relationships, like this one with Oxeltis, aligns with our values and the way we do business, and we are excited to see where we’ll go together.”
Josh Pottel, PhD, CEO of Molecular forecaster Inc.